Try treatment-free remission for chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at whether some people with chronic myeloid leukemia (CML) can stop CML pills and still keep the disease under control. It is for people who are newly diagnosed or whose current CML treatment did not work well or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 14 years old
- Have chronic-phase CML with a specific gene change (Ph+), confirmed by lab tests
- Be either newly diagnosed or have not reached the expected lab response on common CML pills, or be unable to tolerate them
- Have not had a stem cell transplant before starting the study
- If you can get pregnant, have a negative pregnancy test within 7 days before enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
This trial tests a new targeted therapy pill (TGRX-678) for adults with chronic-phase CML who no longer benefit from or cannot tolerate at least three other targeted therapies. The goal is to see if this drug can control the leukemia better.
This trial tests a chemotherapy regimen (thiotepa-containing preparation) combined with a stem cell transplant from a donor to treat chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if this approach helps patients with intermediate-to-high risk disease achieve remission.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.